Experiences with
Targeted therapy17,088 public posts
Want to take advantage of all our features? Just log in!
or
Please join us next Tuesday, October 15th, for our Living Room discussion on Treating EGFR Mutated Non-Small Cell Lung Cancer
First-generation targeted therapy drugs outperformed traditional chemotherapy, but new mutations led to resistance. Researchers developed second and third-generation drugs to combat these resistant mutations.
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
[/u] We don't yet have 10 year survival statistics for the improved combination targeted therapy treatments, because clinical trials for these only commenced within the last 7 years. Hence the question marks in the above PFS plots.